• Price (EUR)100.60
  • Today's Change-1.02 / -1.00%
  • Shares traded0.00
  • 1 Year change+9.95%
  • Beta--
Data delayed at least 15 minutes, as of Jun 30 2022 07:01 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.

  • Revenue in USD (TTM)4.70bn
  • Net income in USD486.90m
  • Incorporated2007
  • Employees17.30k
  • Location
    Catalent Inc14 Schoolhouse RdSOMERSET 08873-1213United StatesUSA
  • Phone+1 (732) 537-6200
  • Fax+1 (732) 537-6480
  • Websitehttps://www.catalent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CTLT:NYQ since
Erytech Pharma SA-Cell Therapy Manufacturing Facility,Princeton,NJDeal completed25 Apr 202225 Apr 2022Deal completed19.11%44.50m
The Vaccine Manufacturing & Innovation CentreDeal completed18 Feb 202218 Feb 2022Deal completed10.24%--
Bettera Holdings LLCAnnounced30 Aug 202130 Aug 2021Announced-16.83%1.00bn
Data delayed at least 15 minutes, as of Jun 30 2022 20:38 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.